A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

European Commission approves Jannsen's CARVYKTI ciltacabtagene autoleucel cilta-cel for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy; it is the first BCMA-targeted treatment approved by the EC
Published: April 22, 2024 by Janssen Pharmaceutical Companies
J&J to present non-clinical studies showcasing the unique properties and promise of nipocalimab as a potential best-in-class treatment for autoantibody-driven diseases; studies to be presented at the American Academy of Neurology’s 2024 Annual Meeting
Published: April 11, 2024 by Janssen Pharmaceutical Companies
J&J reports data from clinical trial shows XARELTO shows reduced risk of significant bleeding and clinical adverse events in elderly and non-elderly patients with nonvalvular atrial fibrillation undergoing coronary artery procedures compared to warfarin
Published: April 08, 2024 by Janssen Pharmaceutical Companies
FDA approves J&J’s CARVYKTI to treat patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy; an estimated 35,000 cases of the disease projected to be diagnosed this year in US
Published: April 06, 2024 by Janssen Pharmaceutical Companies
Janssen Pharmaceutical Companies Spearheading the Fight Against Cancer with Aim for Cure, Strategic Collaborations, and Inclusive Clinical Trials
Published: March 29, 2024 by Industry Intelligence Inc.

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count